Resilience and Eli Lilly Invest $750 Million to Expand GLP-1 Injectable Manufacturing in Cincinnati, Ohio

Resilience and Eli Lilly announced on July 30 a $750 million investment to expand Resilience’s advanced manufacturing operations in the Cincinnati, Ohio region. The expansion adds production of Lilly’s KwikPen injectable device for GLP-1 therapies, including medicines that treat diabetes and obesity.

At least 400 new jobs

The investment will create at least 400 new high-skilled jobs, bringing total Resilience employment in Ohio to more than 1,400 across its facilities.

Operations in early 2027

Site preparation is already underway, with full operations expected to commence in early 2027.

150 million doses and counting

The two companies have produced more than 150 million doses of medicines for U.S. patients through their partnership to date.

Strengthening America’s medicine supply

William S. Marth, President and Chief Executive Officer of Resilience said:

“We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio. Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America’s medicine supply.”